Vertex Pharmaceuticals Inc. Stock

One of the best ways to earn great returns in equity markets is to buy high-quality stocks and hold them for a long time. But it's not always simple to know which corporations have what it takes to

Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500.

Over the past five years, CRISPR Therapeutics' (NASDAQ: CRSP) shares have significantly lagged broader equities. That's despite the company earning approval for its first commercialized medicine,

Drug stocks can be somewhat volatile. Things like clinical setbacks or patent cliffs can sink their stock prices or erode their profits and market share. However, one good thing about companies in

Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered market-beating

Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into

Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals

On February 17, 2026, Tensile Capital Management LP reported selling 384,415 shares of Vertex (NASDAQ:VERX) in the fourth quarter, an estimated $8.32 million trade based on quarterly average

Everyone should save money for retirement, since programs such as Social Security aren't meant to replace workers' entire income and face potential cuts. Building a big nest egg for your post-work

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously considered untreatable. That's why biotechs that specialize in gene

Will the healthcare sector finally rebound in 2026, after underperforming broader equities in recent years? It's hard to know for sure. But rather than avoiding the entire industry because of recent

Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the biotech has made tremendous progress with a promising pipeline

Turning $100,000 into $1 million in a decade requires a compound annual growth rate (CAGR) of almost 26%. That's miles above the market's long-term average. It's also even better than a company like

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors.

Shares of Vertex, a biotech

Investors were snapping up shares of fintech stock Vertex (NASDAQ: VERX) on Thursday. That followed a rather glowing research update from an analyst at a prominent investment bank. With that in its

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics

Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't made the headlines in recent times like companies involved in high-growth areas such as weight loss drugs or artificial intelligence (AI). But this

By all accounts its stock should be in the red today. CRISPR Therapeutics (NASDAQ: CRSP) only reported $864,000 in fourth-quarter revenue after Thursday's closing bell, leading to a loss of $1.37

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of a biotech success story. The company has developed strength in a specialty area and, thanks to that, has delivered a track record of

Vertex Pharmaceuticals (NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report

Vertex Pharmaceuticals (NASDAQ: VRTX) experienced several setbacks last year, sometimes following quarterly updates that weren't as strong as the market expected, or during which it also reported

After underperforming broader equities over the past few years, will the healthcare sector finally rebound and deliver above-average returns from here on out? That's hard to say. Whatever the case

Despite a few setbacks, Vertex Pharmaceuticals (NASDAQ: VRTX) performed pretty well last year, although it lagged the S&P 500. However, things could be very different in 2026. Thanks to several

On November 13, New York City-based Hyperion Capital Advisors disclosed a new position in Vertex (NASDAQ:VERX), acquiring 540,000 shares valued at approximately $13.39 million.

According to a filing